Equillium, Inc.
No SEC Form 4 filings for $EQ in the last 30 days.
See all $EQ insider activity →Equillium, Inc. (EQ) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Exhibit 99.1 Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Clos
Equillium, Inc. (EQ) announced the first dose in its Phase 1 trial of EQ504, a drug for inflammatory diseases. The trial, expected to report topline data in Q2 2027, will evaluate safety, tolerability, and pharmacokinetics. The company also expects to raise $20 million from a milestone closing under an equity private placement.
Piper Sandler maintained a $20 price target for Equillium (EQ), citing Australian regulatory clearance for its EQ504 drug. The stock is down 10% this week. Clear Street also initiated coverage with a $9 target. Equillium plans Phase 1 trials for EQ504, an AhR modulator, with data expected in 2027. The company has a market cap of $91.94M and trades near InvestingPro’s Fair Value estimate.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning EQ (Equillium, Inc.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 0 bearish.
Recent EQ coverage spans financial news, regulation and insider activity.
The funding extends cash runway to 2029 and the clinical start may de‑risk the program.
Positive clinical initiation may lift sentiment and attract speculative buying.
The clearance is a strong catalyst that could lift the stock.
Positive regulatory clearance may lift the stock as the trial progresses.
Regulatory clearance removes a key hurdle, allowing the first human dosing and generation of early safety data.
AlphAI scores every news story that mentions EQ with an AI model for sentiment and relevance, and aggregates insider trades from Equillium, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Equillium, Inc. (EQ) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Exhibit 99.1 Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Clos
2 min readEquillium, Inc. (EQ) announced the first dose in its Phase 1 trial of EQ504, a drug for inflammatory diseases. The trial, expected to report topline data in Q2 2027, will evaluate safety, tolerability, and pharmacokinetics. The company also expects to raise $20 million from a milestone closing under an equity private placement.
2 min readPiper Sandler maintained a $20 price target for Equillium (EQ), citing Australian regulatory clearance for its EQ504 drug. The stock is down 10% this week. Clear Street also initiated coverage with a $9 target. Equillium plans Phase 1 trials for EQ504, an AhR modulator, with data expected in 2027. The company has a market cap of $91.94M and trades near InvestingPro’s Fair Value estimate.
2 min readEquillium, Inc. (EQ) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, Equillium, Inc. (the Company) announced that the Company has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification scheme for its Pha
1 min readEquillium, Inc. (EQ) received regulatory clearance in Australia to begin a Phase 1 clinical trial for EQ504, a treatment for autoimmune and inflammatory disorders. The company plans to start dosing healthy participants by early November 2026, with topline data expected around six months later. EQ504 is designed to treat ulcerative colitis and other inflammatory diseases.
2 min readEquillium, Inc. (EQ) announced preclinical data presentations for its EQ504 program at the 7th International AHR Conference. The data highlights EQ504's potential in treating ulcerative colitis by modulating immune responses and promoting tissue repair. EQ504 is an investigational AhR modulator with a multi-modal mechanism of action. The posters will be available on Equillium's website post-presentation.
1 min readEquillium, Inc. (EQ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expecte
4 min readZedelmayer Christine (Sr. Vice President and COO) sold 14,584 shares of Equillium, Inc. (EQ) at $2.93 on 2026-06-05 under a Rule 10b5-1 trading plan.
1 min readConnelly Stephen (President and CSO) sold 230,975 shares of Equillium, Inc. (EQ) at an average of $3.13 ($2.94–$3.16, $0.72M total) across 2 trades over 2026-06-04 to 2026-06-05.
1 min readEQ Inc. (CVE:EQ) shares fell 3.2% on Monday, trading between C$0.92 and C$0.92 and closing at C$0.92 versus C$0.95 previously. About 2,074 shares changed hands, down 86% from average daily volume. The stock has a C$64.03M market cap and negative P/E (-46).
1 min read
